Drink Product and Use Thereof

Abstract

A drink product having pharmaceutical compositions as an active ingredients of at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed. This invention relates to certain drink products that generally are aqueous solutions containing Genistein (optionally), at least one phosphorylated myoinositol having 1 to 9 phosphate groups (and/or any of the optical isomers thereof) optionally enriched with any or all of myoinositol, optical isomers of myoinositol, electrolytes, flavors, vitamins, free radical scavengers, and sweeteners.

1 . An aqueous liquid formulation comprising:
 (a) water and   (b) at least one phosphorylated member selected from the group consisting of phosphorylated myoinositol having from one to nine phosphate groups inclusive of pyrophosphate groups in which each pyrophosphate is counted as two of the one to nine phosphate groups and/or an optical isomer of said phosphorylated myoinositol, and/or an orally acceptable salt thereof,   (c) optionally Genistein   (d) optionally Ubiquinol, in an orally absorbable form   (e) further optionally comprising one or more components selected from the group consisting of:
 (1) an unphosphorylated member selected from myoinositol and/or an optical isomer thereof; 
 (2) an orally acceptable free radical scavenger other than either of Genistein and Ubiquinol 
 (3) a nutritionally acceptable orally administrable electrolyte; 
 (4) a nutritionally acceptable orally administrable vitamin; 
 (5) a flavor; 
 (6) an orally administrable coloring agent; 
 (7) an orally administrable sweetener; 
 (8) an oral formulation acceptable thickener; 
 (9) an orally administrable, liquid formulation processing aid; and 
 (10) an orally administrable, liquid formulation auxiliary carrier other than water. 
   
     
     
         2 . The formulation of  claim 1  wherein the at least one phosphorylated member is selected from a tetramonophosphate, a pentamonophosphate, a hexamonophosphate, a pentamonophospho-monopyrophosphate, and a tetramonophospho-dipyryophosphate of (a) myoinositol or (b) an optical isomer of myoinositol. 
     
     
         3 . The formulation of  claim 1  wherein when said unphosphorylated inositol or optical isomer thereof is present, it is in the form of the inositol isomer that is present in at least one of the phosphorylated members when such phosphorylated members are viewed without consideration of the phosphorylations involved. 
     
     
         4 . The formulation of  claim 1  wherein when the unphosphorylated inositol or optical isomer thereof is present, it is selected from those members having a different inositol isomeric form from that in any of the phosphorylated members that are present when such phosphorylated members are viewed without consideration of the phosphorylations involved. 
     
     
         5 . A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         6 . A method of preventing damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         7 . A method of treating damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         8 . A method of reducing the risk of developing HIV and/or AIDS and secondary cancers related to HIV and AIDS comprising orally administering the formulation of  claim 1 . 
     
     
         9 . The method of  claim 5  wherein said cancers related to HIV and AIDS is selected from Kaposi sarcoma and non-Hodgkin lymphoma, Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver, blood, soft tissue, and muscular tumors. 
     
     
         10 . A method of preventing a HIV/AIDS related cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         11 . A method of treating a cancer selected from Kaposi sarcoma and non-Hodgkin lymphoma, other AIDS-related cancers selected from Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver, blood, soft tissue, and muscular tumors breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         12 . A method of increasing T cells and or inhibiting HIV related CD4 reduction comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         13 . A method for blocking the communication between a HIV cell surface to internal cellular compartment comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         14 . A method for preventing an HIV particle from entering the internal cellular compartments thereby preventing the spread of the infection comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         15 . A method of reducing the risk of adverse effects of common and current drug toxicities' associated with current anti-viral therapies comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         16 . A method of reducing drug resistance known to occur with current drugs because it's a plant based product comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         17 . A method for both prevention HIV infection of resting CD4 T-cells, viral DNA synthesis, and/or viral nuclear migration comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         18 . A method for preventing Gag-NA chaperone, inositol does that interaction prior to membrane binding in HIV comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         19 . A method for inhibiting the replication of HIV-1 comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         20 . A method for AP3B1 regulation and HIV-1 Gag release comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         21 . The formulation of  claim 1  which is a liquid nutritional supplement. 
     
     
         22 . The formulation of  claim 1  which is an orally administered product. 
     
     
         23 . A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         24 . A method of preventing damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         25 . A method of treating damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         26 . A method of reducing the risk of developing a cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, wet tumors, multiple myeloma, brain, throat, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         27 . A method of preventing cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, wet tumors, multiple myeloma, brain, throat, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         28 . A method of treating a cancer selected from cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, wet tumors, multiple myeloma, brain, throat, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         29 . A method of reducing adverse effects of diagnostic radiation treatments in a patient in need thereof comprising orally administering to such a patient, before, during, or after said diagnostic radiation treatment, the formulation of  claim 1 . 
     
     
         30 . A method of reducing the risk of adverse effects of environmental radiation exposure to a human or animal in need thereof comprising administering to said human or said animal respectively, before, during, or after said environmental, radiation exposure, the composition of  claim 1 . 
     
     
         31 . The method of  claim 30  wherein said environmental radiation exposure is selected from the group consisting of:
 a) extreme elevation above sea level; 
 b) flying; 
 c) going into planetary orbit or further into space; and 
 d) mining, purification, or handling of radioactive materials. 
 
     
     
         32 . A method of reducing the risk of adverse effects of environmental exposure to at least one of air pollutants, cigarette smoke, and/or other free oxygen radical generating substances in a human or animal comprising administering to said human or said animal respectively, before, during, or after said exposure, the composition of  claim 1 . 
     
     
         33 . A method of reducing the risk of or treating a neurodegenerative disease related to environmental condition exposure comprising administering the composition of  claim 1 . 
     
     
         34 . The method of  claim 33 , wherein the neurodegenerative disease is Alzheimer's Disease and/or brain cancer. 
     
     
         35 . A method of prophylactic treatment of a subject to prevent or slow the progression of an HIV infection wherein said subject is known to be or suspected to be at risk of an HIV infection due to actual or suspected exposure to HIV virus or has been determined to have a detectable titer of HIV/AID virus or surrogate markers therefor and has not yet presented with clinical symptoms of HIV/AIDS comprising administering a composition of  claim 1  to said subject. 
     
     
         36 . The aqueous liquid formulation of  claim 1  wherein said Ubiquinol is present. 
     
     
         37 . The aqueous liquid formulation of  claim 36  wherein said Ubiquinol is in the form of Qunol Liquid Co Q10 or other form as set forth in U.S. Pat. No. 6,455,072. 
     
     
         38 . The formulation of  claim 1  wherein said phosphorylated member is myoinositol hexaphosphate or optical isomer thereof and said unphosphorylated myoinositol or optical isomer thereof is present and is unphosphorylated myoinositol. 
     
     
         39 . The formulation of  claim 38  or the composition of  claim 38  wherein said phosphorylated member is myoinositol hexaphosphate and said unphosphorylated myoinositol or optical isomer thereof is myoinositol per se. 
     
     
         40 . A composition comprising:
 (a) water and   (b) at least one phosphorylated member selected from the group consisting of phosphorylated myoinositol having from one to nine phosphate groups inclusive of pyrophosphate groups in which each pyrophosphate is counted as two of the one to nine phosphate groups and/or an optical isomer of said phosphorylated myoinositol, and/or an orally acceptable salt thereof,   (c) optionally Genistein   (d) optionally Ubiquinol, in an orally absorbable form   (e) further optionally comprising one or more components selected from the group consisting of:
 (1) an unphosphorylated member selected from myoinositol and/or an optical isomer thereof; 
 (2) an orally acceptable free radical scavenger other than either of Genistein and Ubiquinol 
 (3) a nutritionally acceptable orally administrable electrolyte; 
 (4) a nutritionally acceptable orally administrable vitamin; 
 (5) a flavor; 
 (6) an orally administrable coloring agent; 
 (7) an orally administrable sweetener; 
 (8) an oral composition acceptable thickener; 
 (9) an orally administrable, liquid formulation processing aid; and 
 (10) an orally administrable, liquid formulation auxiliary carrier other than water. 
   
     
     
         41 . The composition of  claim 40  wherein the at least one phosphorylated member is selected from a tetramonophosphate, a pentamonophosphate, a hexamonophosphate, a pentamonophospho-monopyrophosphate, and a tetramonophospho-dipyryophosphate of (a) myoinositol or (b) an optical isomer of myoinositol. 
     
     
         42 . The composition of  claim 40  wherein when said unphosphorylated inositol or optical isomer thereof is present, it is in the form of the inositol isomer that is present in at least one of the phosphorylated members when such phosphorylated members are viewed without consideration of the phosphorylations involved. 
     
     
         43 . The composition of  claim 40  wherein when the unphosphorylated inositol or optical isomer thereof is present, it is selected from those members having a different inositol isomeric form from that in any of the phosphorylated members that are present when such phosphorylated members are viewed without consideration of the phosphorylations involved. 
     
     
         44 . The composition of  claim 40  wherein said Ubiquinol is present. 
     
     
         45 . The composition of  claim 44  wherein said Ubiquinol is in the form of Qunol Liquid Co Q10 or other form as set forth in U.S. Pat. No. 6,455,072. 
     
     
         46 . The composition of  claim 40  wherein said phosphorylated member is myoinositol hexaphosphate or optical isomer thereof and said unphosphorylated myoinositol or optical isomer thereof is present and is unphosphorylated myoinositol. 
     
     
         47 . The composition of  claim 49  wherein said phosphorylated member is myoinositol hexaphosphate and said unphosphorylated myoinositol or optical isomer thereof is myoinositol per se. 
     
     
         48 . A method of making a formulation of  claim 1  comprising dissolving the  claim 1  components into an aqueous based carrier. 
     
     
         49 . A method of making a composition of  claim 40  comprising dissolving the  claim 40  components into an aqueous based carrier.